IL226345D0 - Antiviral compounds - Google Patents

Antiviral compounds

Info

Publication number
IL226345D0
IL226345D0 IL226345A IL22634513A IL226345D0 IL 226345 D0 IL226345 D0 IL 226345D0 IL 226345 A IL226345 A IL 226345A IL 22634513 A IL22634513 A IL 22634513A IL 226345 D0 IL226345 D0 IL 226345D0
Authority
IL
Israel
Prior art keywords
antiviral compounds
antiviral
compounds
Prior art date
Application number
IL226345A
Other languages
Hebrew (he)
Other versions
IL226345A (en
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201161560654P priority Critical
Priority to PCT/US2012/065681 priority patent/WO2013075029A1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of IL226345D0 publication Critical patent/IL226345D0/en
Publication of IL226345A publication Critical patent/IL226345A/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47324426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL226345(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/893Liver disorder
    • Y10S514/894Hepatitis
IL226345A 2011-11-16 2013-05-13 Antiviral compounds IL226345A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161560654P true 2011-11-16 2011-11-16
PCT/US2012/065681 WO2013075029A1 (en) 2011-11-16 2012-11-16 Condensed imidazolylimidazoles as antiviral compounds

Publications (2)

Publication Number Publication Date
IL226345D0 true IL226345D0 (en) 2013-07-31
IL226345A IL226345A (en) 2016-03-31

Family

ID=47324426

Family Applications (5)

Application Number Title Priority Date Filing Date
IL226345A IL226345A (en) 2011-11-16 2013-05-13 Antiviral compounds
IL244122A IL244122D0 (en) 2011-11-16 2016-02-15 Antiviral compounds
IL244124A IL244124D0 (en) 2011-11-16 2016-02-15 Antiviral compounds
IL244123A IL244123D0 (en) 2011-11-16 2016-02-15 Antiviral compounds
IL252345A IL252345D0 (en) 2011-11-16 2017-05-17 Antiviral compounds

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL244122A IL244122D0 (en) 2011-11-16 2016-02-15 Antiviral compounds
IL244124A IL244124D0 (en) 2011-11-16 2016-02-15 Antiviral compounds
IL244123A IL244123D0 (en) 2011-11-16 2016-02-15 Antiviral compounds
IL252345A IL252345D0 (en) 2011-11-16 2017-05-17 Antiviral compounds

Country Status (37)

Country Link
US (12) US20130164260A1 (en)
EP (3) EP2635588B1 (en)
JP (4) JP6082749B2 (en)
KR (3) KR101890400B1 (en)
CN (2) CN105837584B (en)
AP (1) AP201306877A0 (en)
AU (1) AU2012318253B8 (en)
BR (1) BR112013012091A2 (en)
CA (2) CA2815082C (en)
CL (1) CL2013001428A1 (en)
CO (1) CO6791562A2 (en)
CR (1) CR20130231A (en)
CY (1) CY1116987T1 (en)
DK (2) DK2635588T3 (en)
EA (3) EA030941B1 (en)
EC (1) ECSP13012790A (en)
ES (2) ES2687291T3 (en)
HK (1) HK1188989A1 (en)
HR (2) HRP20150725T1 (en)
HU (2) HUE039966T2 (en)
IL (5) IL226345A (en)
LT (1) LT2907816T (en)
MA (1) MA34727B1 (en)
MD (2) MD4521C1 (en)
ME (1) ME02196B (en)
MX (2) MX346729B (en)
NZ (3) NZ720856A (en)
PE (2) PE20141163A1 (en)
PH (1) PH12015502839A1 (en)
PL (2) PL2907816T3 (en)
PT (2) PT2635588E (en)
RS (2) RS57638B1 (en)
SG (1) SG10201700947UA (en)
SI (2) SI2635588T1 (en)
SM (1) SMT201500197B (en)
UA (1) UA110354C2 (en)
WO (1) WO2013075029A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2604620T (en) 2003-05-30 2016-09-12 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
RS56654B1 (en) 2009-05-13 2018-03-30 Gilead Pharmasset Llc Antiviral compounds
KR101835474B1 (en) 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 Antiviral compounds
EP2730572B1 (en) 2011-07-09 2015-09-16 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
ES2659216T3 (en) 2011-09-16 2018-03-14 Gilead Pharmasset Llc Methods for the treatment of HCV
MD4521C1 (en) * 2011-11-16 2018-05-31 Gilead Pharmasset Llc. Antiviral compounds based on condensed imidazolyl-dihydroisochromeno-naphthoimidazols
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10032995B2 (en) 2013-02-07 2018-07-24 Kyulux, Inc. Compound having diazatriphenylene ring structure, and organic electroluminescent device
WO2014185995A1 (en) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Hepatitis c treatments with sofosbuvir
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
EP3019196B1 (en) * 2013-07-09 2018-06-06 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
CN105530933B (en) 2013-07-17 2018-12-11 百时美施贵宝公司 For treating the combination product comprising biphenyl derivatives of HCV
CN105517540B (en) 2013-08-27 2019-08-23 吉利德制药有限责任公司 The compound preparation of two kinds of antiviral compounds
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN104418784B (en) * 2013-09-04 2019-02-19 浙江九洲药业股份有限公司 A kind of method for splitting of Internmediate of anti viral medicine
EP3087086B1 (en) 2013-12-23 2018-11-07 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
TW201609745A (en) * 2014-06-11 2016-03-16 吉李德製藥公司 Solid forms of an antiviral compound
TW201609744A (en) * 2014-06-11 2016-03-16 吉李德製藥公司 Processes for preparing antiviral compounds
CN105801462A (en) * 2014-12-29 2016-07-27 重庆博腾制药科技股份有限公司 (4S)-N-Boc-4-methoxymethyl-L-proline synthesis method
CN104586802B (en) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 A kind of pharmaceutical composition containing Suo Feibuwei
CN106008552A (en) * 2015-03-01 2016-10-12 南京圣和药业股份有限公司 Benzo[e]pyrazolo[1, 5-c][1, 3]oxazine compound and application thereof
US10487067B2 (en) * 2015-10-08 2019-11-26 Mylan Laboratories Limited Process for the preparation of velpatasvir
CN105294713A (en) * 2015-10-09 2016-02-03 重庆康施恩化工有限公司 Velpatasvir intermediate and preparation method thereof
CN105801553B (en) * 2016-04-12 2018-06-19 爱斯特(成都)生物制药股份有限公司 A kind of preparation method of Benzochromene derivatives
CN106916134A (en) * 2016-04-14 2017-07-04 苏州楚凯药业有限公司 A kind of preparation method of 10,11- dihydros -5H- benzos [d] naphtho- [2,3-b] pyrone derivative
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
EP3452038A4 (en) * 2016-05-05 2020-01-15 Laurus Labs Ltd Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
MX2018014377A (en) 2016-05-27 2019-03-14 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors.
BR102017011025A2 (en) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
WO2018006811A1 (en) * 2016-07-08 2018-01-11 深圳市塔吉瑞生物医药有限公司 Substituted imidazolyl compound and pharmaceutical composition thereof
KR101887969B1 (en) * 2016-08-30 2018-08-13 한국과학기술연구원 Carbazole compounds having anti-virus activity
CN107573380A (en) * 2016-11-30 2018-01-12 上海博志研新药物技术有限公司 Wei Patawei intermediates, preparation method and application
CN106831737A (en) * 2017-02-27 2017-06-13 上海众强药业有限公司 The preparation of Wei Patawei and its derivative
CN107501280A (en) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 A kind of Wei Patawei synthetic method
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of il4 receptor targeted agents, interferon gamma, and interferon alpha for use in treating ovarian cancer
CN108276421B (en) * 2018-02-13 2019-08-06 浙江永太药业有限公司 A kind of synthetic method of Wei Patawei

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
AU651835B2 (en) 1990-06-13 1994-08-04 Arnold Glazier Phosphorous prodrugs
DE10399025I2 (en) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Active substance precursors of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
ES2456702T3 (en) 2003-05-09 2014-04-23 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
PL382845A1 (en) 2004-07-16 2008-01-21 Gilead Sciences, Inc. Anti- virus compounds
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI442947B (en) 2006-12-07 2014-07-01 Daiichi Sankyo Co Ltd Film coating formulations of improved stability
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009102620A2 (en) * 2008-02-11 2009-08-20 Qualcomm Mems Technologies Inc. Methods for measurement and characterization of interferometric modulators
PT2250163E (en) 2008-02-12 2012-06-01 Squibb Bristol Myers Co Hepatitis c virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2010008863A (en) 2008-02-13 2010-09-07 Squibb Bristol Myers Co Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors.
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010062821A1 (en) * 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
PE20120207A1 (en) 2008-12-03 2012-03-31 Presidio Pharmaceuticals Inc Naphthalene derivatives as inhibitors of HCV NS5A
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
SG10201400235PA (en) 2009-02-27 2014-07-30 Enanta Pharm Inc Hepatitis c virus inhibitors
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
PE20120773A1 (en) 2009-03-27 2012-07-19 Presidio Pharmaceuticals Inc Tricyclic fused ring compounds as inhibitors of hepatitis C virus
CA2760205A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
RS56654B1 (en) * 2009-05-13 2018-03-30 Gilead Pharmasset Llc Antiviral compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112012003578A2 (en) * 2009-09-04 2015-09-08 Glaxosmithkline Llc compound, pharmaceutically acceptable salt, sulfate salt, pharmaceutical composition, method for treating a viral infection, and use of a compound or salt.
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2782024A1 (en) * 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104530079B (en) * 2009-12-18 2017-10-20 北京凯因科技股份有限公司 The new inhibitor that hepatitis C virus is replicated
CA2785488A1 (en) * 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
SG183526A1 (en) 2010-03-09 2012-09-27 Merck Sharp & Dohme Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2616461A4 (en) 2010-08-26 2014-03-26 Rfs Pharma Llc Potent and selective inhibitors of hepatitis c virus
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
KR101835474B1 (en) 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 Antiviral compounds
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
MD4521C1 (en) 2011-11-16 2018-05-31 Gilead Pharmasset Llc. Antiviral compounds based on condensed imidazolyl-dihydroisochromeno-naphthoimidazols
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
CN105517540B (en) 2013-08-27 2019-08-23 吉利德制药有限责任公司 The compound preparation of two kinds of antiviral compounds
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TW201609744A (en) 2014-06-11 2016-03-16 吉李德製藥公司 Processes for preparing antiviral compounds
TW201609745A (en) 2014-06-11 2016-03-16 吉李德製藥公司 Solid forms of an antiviral compound
JP2016051146A (en) 2014-09-02 2016-04-11 ウシオ電機株式会社 Optical detection device

Also Published As

Publication number Publication date
HRP20150725T1 (en) 2015-08-14
BR112013012091A2 (en) 2019-09-10
AU2012318253B8 (en) 2015-08-13
US20140112885A1 (en) 2014-04-24
JP2019206597A (en) 2019-12-05
US20130177530A1 (en) 2013-07-11
CA2884712A1 (en) 2013-05-23
ECSP13012790A (en) 2013-10-31
SMT201500197B (en) 2015-09-07
MD4521C1 (en) 2018-05-31
US20130164260A1 (en) 2013-06-27
IL244123D0 (en) 2016-04-21
AU2012318253A8 (en) 2015-08-13
PH12015502839A1 (en) 2019-05-15
WO2013075029A1 (en) 2013-05-23
EA023644B1 (en) 2016-06-30
US9221833B2 (en) 2015-12-29
MX361735B (en) 2018-12-14
EP2635588A1 (en) 2013-09-11
ME02196B (en) 2016-02-20
AU2012318253A1 (en) 2013-05-30
JP2016199593A (en) 2016-12-01
HUE027733T2 (en) 2016-10-28
ES2687291T3 (en) 2018-10-24
HUE039966T2 (en) 2019-02-28
HK1188989A1 (en) 2015-11-20
DK2635588T3 (en) 2015-09-07
DK2907816T3 (en) 2018-09-24
US20180186806A1 (en) 2018-07-05
EA030941B1 (en) 2018-10-31
US20190276468A1 (en) 2019-09-12
US9868745B2 (en) 2018-01-16
RS57638B1 (en) 2018-11-30
EA201390576A1 (en) 2013-11-29
MD20150091A2 (en) 2016-02-29
MD4403C1 (en) 2016-09-30
PE20141163A1 (en) 2014-09-21
SG10201700947UA (en) 2017-03-30
AP201306877A0 (en) 2013-05-31
US20150299213A1 (en) 2015-10-22
EA201591244A1 (en) 2016-02-29
MX346729B (en) 2017-03-30
US9051340B2 (en) 2015-06-09
KR101890400B1 (en) 2018-08-21
EP2907816B1 (en) 2018-06-13
CR20130231A (en) 2013-09-19
JP6082749B2 (en) 2017-02-15
KR20140096239A (en) 2014-08-05
MD4403B1 (en) 2016-02-29
US20140309432A1 (en) 2014-10-16
CY1116987T1 (en) 2017-04-05
MA34727B1 (en) 2013-12-03
AU2012318253B2 (en) 2015-08-06
CO6791562A2 (en) 2013-11-14
KR20190121406A (en) 2019-10-25
US20180244683A1 (en) 2018-08-30
IL252345D0 (en) 2017-07-31
EP2635588B1 (en) 2015-06-10
NZ737924A (en) 2019-06-28
PL2907816T3 (en) 2019-03-29
NZ720856A (en) 2017-12-22
PE20171444A1 (en) 2017-09-29
EP3431477A1 (en) 2019-01-23
CN105837584A (en) 2016-08-10
KR20180095119A (en) 2018-08-24
MD4521B1 (en) 2017-10-31
IL244124D0 (en) 2016-04-21
KR102036469B1 (en) 2019-10-24
LT2907816T (en) 2018-09-10
US20150141326A1 (en) 2015-05-21
CN105837584B (en) 2018-07-13
US8921341B2 (en) 2014-12-30
SI2907816T1 (en) 2018-10-30
CA2815082A1 (en) 2013-05-23
PL2635588T3 (en) 2015-10-30
US20170145027A1 (en) 2017-05-25
SI2635588T1 (en) 2015-10-30
CL2013001428A1 (en) 2014-06-27
CN103328480A (en) 2013-09-25
CA2815082C (en) 2015-07-07
PT2635588E (en) 2015-09-14
US8575135B2 (en) 2013-11-05
PT2907816T (en) 2018-10-18
US8940718B2 (en) 2015-01-27
JP2018024705A (en) 2018-02-15
HRP20181384T1 (en) 2018-12-28
IL244122D0 (en) 2016-04-21
JP2015512860A (en) 2015-04-30
US20130156732A1 (en) 2013-06-20
US9809600B2 (en) 2017-11-07
UA110354C2 (en) 2015-12-25
IL226345A (en) 2016-03-31
ES2544107T3 (en) 2015-08-27
MX2013005575A (en) 2013-09-05
RS54207B1 (en) 2015-12-31
NZ610525A (en) 2017-05-26
EP2907816A1 (en) 2015-08-19
US20160083394A1 (en) 2016-03-24
CN103328480B (en) 2016-05-25
MD20130029A2 (en) 2013-09-30
EA201890333A1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
PL2602176T3 (en) Chainring
GB201114103D0 (en) Novel compounds
HK1195016A1 (en) Protein-polymer-drug conjugates --
AP201407488A0 (en) Cyclopropaneamine compound
HRP20150725T1 (en) Condensed imidazolylimidazoles as antiviral compounds
IL233154D0 (en) Compounds
PL2640719T3 (en) Antiviral compounds
IL226004D0 (en) Novel antiviral compounds
GB201106799D0 (en) Novel compounds
GB201107325D0 (en) Novel compounds
GB201118652D0 (en) New compounds
HK1203196A1 (en) Substituted benzylpyrazoles
GB201106395D0 (en) Compounds
EP2755962A4 (en) Azaindazoles
TWI561522B (en) Substituted imidazopyridinyl-aminopyridine compounds
GB201118784D0 (en) Djml
IL231781D0 (en) Anti-viral compounds
EP2580190A4 (en) New antiviral compounds
GB201118675D0 (en) New compounds
GB201118654D0 (en) New compounds
GB201116641D0 (en) Novel compounds
HK1214594A1 (en) Antiviral compounds
GB201109763D0 (en) Compounds
IL230280A (en) Breastshield unit
GB201112607D0 (en) Novel compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed